In general, the present invention relates to small molecule inhibitors of the heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of neurodegenerative diseases.

The present Invention relates to long acting pharmaceutical compositions of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine), useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.

A process for making clofarabine comprising: fluorinating a compound of formula VII wherein each R4 is independently a hydroxy protecting group OR6 is a leaving group with a fluorinating agent in the presence of guanidine carbonate to give a compound of formula VIII: wherein R4 is as defined above; and deprotecting the compound of formula VIII to give the clofarabine.

The invention relates to the novel adenine derivatives of formula (I) wherein R1 R2 R3 X and Y are defined as in claim 1. The inventive derivatives are HSP90 inhibitors and can be used for producing a drug for treating diseases in which HSP90 inhibition regulation and/or modulation plays a role.

Compounds of formula (I)wherein Ris Calkylamino or Calkoxy; Ris a group having the structuren is an integer having a value of 1 to 6; Het is a 6-membered saturated heterocycle containing one nitrogen atom wherein Het is attached to the -(CH)- moiety at any carbon atom of the heterocycle; Ris hydrogen Calkyl or CcycloalkylCalkyl; and salts thereof are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders for example the treatment...

Disclosed are (N)-methanocarba adenine nucleosides e.g. of formula (I) as highly potent A